mrr pvt. Ltd.

Asia Pacific Type 2 Diabetes Mellitus Therapeutics Market Boosted By Innovations And Improving Competition

Press Release   •   Feb 20, 2017 12:59 IST has added a new research report to its database on the therapeutics in the healthcare industry. The report, titled “Type 2 Diabetes Mellitus Therapeutics In Asia-Pacific Markets To 2021 - Increasing Usage Of Newer Therapies And Expanding Treatment Population To Encourage Robust Growth,” provides its users with an in-depth understanding of T2DM in terms of its symptoms, diagnosis, therapeutic options, epidemiology, pathophysiology, and etiology. The report also helps identify the various strategies adopted by vendors operating in this market in terms of products as well as the competitive landscape that plays an important role in conjunction with the factors influencing the prevailing market trends.

Diabetes mellitus forms a characteristic group of metabolic disorders. They are usually typified according to chronic hyperglycemia high levels of glucose. These factors are primarily caused by defective action or secretion of insulin, or even a combined fault of both. Damage caused by chronic hyperglycemia is usually long-term and includes damage to the blood vessels and the heart, nerves, kidneys, and eyes. Nearly 85.0%, and under 90.0%, of the diabetic patients in the world are type 2 diabetic.

According to the report, the Asia Pacific T2DM therapeutics market will exhibit a CAGR of 7.70% between 2014 and 2021. The market was recorded at US$6.07 bn in 2013 and is expected to reach to more than US$10.20 bn before the end of 2021. The report therefore analyzes the largest contributors to the current size of the Asia Pacific T2DM therapeutics market and what it could be within the given forecast period.

For Sample Copy, click here:

The report also provides analytical data on the clinical trials that have been conducted in the Asia Pacific T2DM therapeutics market since 2006. Through this analysis, the report reveals that 54.0% of the total failures occurred in the second phase, which makes it the phase with the largest number of failures. The overall rate of attrition in the therapeutic market for T2DM is currently 82.60%. The report further provides an accurate assessment on how these failure rates change according to the stage of development of a product. Other factors that change the failure rate, as discussed in the report, include the action mechanism and the type of molecule.

The report also provides a detailed explanation of how the increasing prevalence of T2DM is propelling growth of the Asia Pacific T2DM therapeutics market. There is an increase in the consumption of new and innovative therapies for T2DM. This growth rate holds positive despite the currently increasing reduction in revenue generation due to the higher sales of generic drugs. These generic drugs that are created after the expiration of patents are on the rise, threatening the growth rate of the Asia Pacific T2DM therapeutics market. Another factor threatening the growth of this market is the increasing number of pipeline molecules in it.

To order report Call Toll Free: 866-997-4948 or send an email on